| N0 | 18 | 36% | 14 | (57.6%) | 4 | (0%) | 0.005§ |
| N1 | 6 | 12% | 5 | (21.2%) | 1 | (0%) | |
| N2 | 16 | 32% | 3 | (18.2%) | 13 | (55.6%) | |
| N3 | 10 | 20% | 1 | (3%) | 9 | (44.4%) | |
| Lymph node |
|
|
|
|
|
|
|
| Negative | 18 | 36% | 18 | (57.6%) | 0 | (0%) | <0.001‡ |
| Positive | 32 | 64% | 15 | (42.4%) | 27 | (100%) | |
| M |
|
|
|
|
|
|
|
| M0 | 40 | 80% | 26 | (55.3%) | 21 | (44.7%) | 0.011‡ |
| M1 | 10 | 20% | 2 | (15.4%) | 11 | (48.6%) | |
| AJCC Stage group |
|
|
|
|
|
|
|
| Stage I | 8 | 16% | 8 | (27.3%) | 0 | (0%) | <0.001§ |
| Stage II | 10 | 20% | 8 | (42.4%) | 2 | (0%) | |
| Stage III | 22 | 44% | 7 | (30.3%) | 15 | (40.7%) | |
| Stage IV | 10 | 20% | 0 | (0%) | 10 | (59.3%) | |
| FOXC2 |
|
|
|
|
|
|
|
| Low | 20 | 40% | 21.30 | ±18.41 | 77.48 | ±15.41 |
|
| High | 30 | 60% | 20 | (0 - 56) | 80 | (44 - 97) |